ArticleScientific reports2018
Blood plasma/IgG N-glycome biosignatures associated with major depressive disorder symptom severity and the antidepressant response.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 38 citations in OpenAlex.
- Site-specific N-glycosylation alterations in serum proteins across subtypes of adolescent depressive disorder.BMC psychiatry · 2026Article
- Unraveling the enigma: Post-translational modifications in psychiatric disorders and their regulatory mechanisms.Journal of translational internal medicine · 2026Article
- Tracing fucosylation and astrocyte-associated pathogenic pattern in major depressive disorder: evidence from machine learning-based multi-omics and clinical validation.Frontiers in neuroscience · 2026Article
- Abnormal O-glycan sialylation in the mPFC contributes to depressive-like behaviors in male mice.Science advances · 2025Article
- The emerging landscape of brain glycosylation: from molecular complexity to therapeutic potential.Experimental & molecular medicine · 2025Review
- Glycosylation changes of vWF in circulating extracellular vesicles to predict depression.Scientific reports · 2024Article
- Toward molecular diagnosis of major depressive disorder by plasma peptides using a deep learning approach.Briefings in bioinformatics · 2024Article
- Identification of Schizophrenia Susceptibility Loci in the Urban Taiwanese Population.Medicina (Kaunas, Lithuania) · 2024Article
- Predicting psychiatric risk: IgG N-glycosylation traits as biomarkers for mental health.Frontiers in psychiatry · 2024Article
- Glycosylation and behavioral symptoms in neurological disorders.Translational psychiatry · 2023Review
- The Association of the Polymorphisms in theInternational journal of molecular sciences · 2023Article
- Article
- Review
- Integrated Metabolomics and Proteomics Analysis of Urine in a Mouse Model of Posttraumatic Stress Disorder.Frontiers in neuroscience · 2022Article
- Post-translational Modifications in Brain Diseases: A Future for Biomarkers.Advances in experimental medicine and biology · 2022Article
- MS-based glycomics: An analytical tool to assess nervous system diseases.Frontiers in neuroscience · 2022Review
- Molecular Mechanisms Associated with Antidepressant Treatment on Major Depression.Complex psychiatry · 2021Review
- An integrative network analysis framework for identifying molecular functions in complex disorders examining major depressive disorder as a test case.Scientific reports · 2021Article
- A Load to Find Clinically Useful Biomarkers for Depression.Advances in experimental medicine and biology · 2021Article
- The Relationship between rs534654 Polymorphism in TMEM165 Gene and Increased Risk of Bipolar Disorder Type 1.International journal of molecular and cellular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While N-linked glycosylation has been extensively studied in the context of inflammatory and metabolic disorders, its relationship with major depressive disorder (MDD) and antidepressant treatment response has not been investigated. In our exploratory study, we analysed N-glycan profiles in blood plasma samples collected from MDD patients (n = 18) and found gender-dependent correlations with severity of depressive symptoms prior to initiating antidepressant treatment. In addition, several N-glycosylation traits showed gender-dependent associations with clinical antidepressant response. Follow up proteomics analysis in peripheral blood mononuclear cells (PBMCs) collected from MDD patients (n = 20) identified baseline and post-antidepressant treatment pathway differences between responder and non-responder patients. Reactome data analysis further delineated potential biological reaction differences between responder and non-responder patients. Our preliminary results suggest that specific glycosylation traits are associated with depressive symptom severity and antidepressant response and may be of use as biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.